Non Hodgkin Lymphoma Disease Statistics In US 2026 | Treatments & Facts

What Is Non Hodgkin Lymphoma Disease?

Non-Hodgkin lymphoma (NHL) is a cancer that begins in the lymphatic system, the network of vessels, nodes, and organs that helps the body fight infection. It develops when white blood cells called lymphocytes — mostly B-cells, but sometimes T-cells or NK cells — grow abnormally and multiply out of control. Because lymph tissue runs through nearly every part of the body, NHL can start almost anywhere, including the neck, chest, abdomen, spleen, or bone marrow. Doctors currently recognize more than 70 distinct subtypes of NHL, ranging from slow-growing (indolent) forms like follicular lymphoma to fast-moving (aggressive) forms like diffuse large B-cell lymphoma (DLBCL), which happens to be the most frequently diagnosed subtype in American adults.

Heading into 2026, non-Hodgkin lymphoma remains one of the most commonly diagnosed blood cancers in the United States, ranking as the 8th most common cancer in the country. It doesn’t discriminate strictly by age — it shows up in children, teenagers, and young adults too — but the risk climbs steadily after age 50, and the typical patient being diagnosed today is around 68 years old. The good news, based on federal cancer-registry data, is that this disease has been getting somewhat less common and considerably more survivable over the last decade, largely a reflection of earlier detection tools and major advances in targeted and immune-based treatments that simply didn’t exist twenty years ago.

Interesting Facts About Non Hodgkin Lymphoma In US 2026

Data Source: National Cancer Institute, Surveillance, Epidemiology, and End Results (SEER) Program, Cancer Stat Facts; American Cancer Society, Cancer Facts & Figures 2026.

The number that stands out immediately is the 79,320 new cases projected for 2026 against 19,970 estimated deaths — a ratio that, on its face, looks alarming until you pair it with the 74.3% five-year relative survival rate. That combination tells the real story: NHL is being diagnosed in tens of thousands of Americans every year, yet roughly three out of four people diagnosed today are still alive five years later, a figure that has climbed substantially compared to just a few decades ago. The 872,940 prevalence figure is equally telling because it captures everyone currently living with or having survived NHL, not just new diagnoses, which means the healthcare system is managing a very large, ongoing population of patients and survivors, not merely treating new cases in isolation.

The median age at diagnosis (68) versus the median age at death (76) also deserves attention, because the eight-year gap suggests that even patients who are diagnosed later in life are, on average, living for a meaningful stretch of time afterward. Meanwhile, the lifetime risk of about 2.0% puts NHL into perspective compared to more common cancers like breast or prostate cancer, reminding readers that while NHL is serious, it is statistically less common than the “top tier” cancers, yet common enough that most people will know someone affected by it in their lifetime. These facts collectively frame NHL as a disease that is both manageable and still a significant public health concern in the United States as of 2026.

New Non-Hodgkin Lymphoma Cases And Deaths In The US 2026

Data Source: National Cancer Institute, SEER Cancer Stat Facts; Centers for Disease Control and Prevention, National Center for Health Statistics.

Visual Snapshot — New Cases vs. Deaths (per 100,000):

New Case Rate    ████████████████████ 18.7
Death Rate       █████               4.8

Looking purely at the raw counts, 79,320 new NHL cases translate into an age-adjusted incidence rate of 18.7 per 100,000 Americans annually, while the 19,970 projected deaths correspond to a rate of 4.8 per 100,000. What jumps out here is the gap between the incidence rate and the death rate — nearly a four-to-one ratio — which is a strong statistical signal that most people diagnosed with NHL today are not dying from it within the observation window, largely thanks to modern chemoimmunotherapy regimens and newer targeted drugs reaching patients faster than in prior decades.

It’s also worth noting that these figures are drawn from two slightly different time windows (2019–2023 for incidence, 2020–2024 for mortality), which is standard practice in federal cancer surveillance because death data typically lags behind diagnosis data by a year or two as follow-up records get finalized.

Non-Hodgkin Lymphoma Ranking Among Common Cancers In US 2026

Data Source: National Cancer Institute, SEER Cancer Stat Facts, based on American Cancer Society projections.

Visual Snapshot — Top 10 Cancers by New Cases (2026, in thousands):

Prostate      █████████████████████████████████ 334k
Breast(F)     ████████████████████████████████  322k
Lung          ██████████████████████            229k
Colorectal    ████████████████                  159k
Melanoma      ███████████                       112k
Bladder       ████████                           85k
Kidney        ████████                           80k
NHL           ███████                            79k
Uterine       ██████                             68k
Leukemia      ██████                             68k

Placing non-Hodgkin lymphoma at rank #8 among all cancers diagnosed in the United States in 2026 gives readers useful context: it sits just behind kidney cancer and just ahead of uterine cancer in terms of raw new-case volume, making it a solidly “top-ten” cancer rather than a rare disease. What’s particularly interesting is that NHL’s death count (19,970) is proportionally higher relative to its case count than several cancers ranked above it, such as melanoma, which has a much lower death-to-case ratio — this reflects the fact that NHL, especially aggressive subtypes, can still be a difficult cancer to treat successfully in a meaningful share of patients despite modern therapy.

NHL is neither a “minor” cancer nor one of the true heavy-hitters like lung or breast cancer — it occupies a middle tier that still affects tens of thousands of families every year. This ranking is also useful for readers trying to gauge risk relative to other well-known cancers; NHL’s case volume is roughly a quarter of breast cancer’s, but its share of total cancer deaths (3.2%) is proportionally significant enough that public health agencies continue to prioritize lymphoma research funding and treatment access initiatives nationwide.

Non-Hodgkin Lymphoma Incidence Rate By Race And Ethnicity In US 2026

Data Source: National Cancer Institute, SEER 21 Registries, 2019–2023, age-adjusted.

Visual Snapshot — Male Incidence Rate by Race/Ethnicity:

Non-Hispanic White        ████████████████████████ 24.2
All Races                 ██████████████████████    22.4
Hispanic                  █████████████████████     20.5
AI/Alaska Native          █████████████████         17.6
Non-Hispanic Black        █████████████████         16.9
Asian/Pacific Islander    ████████████████           16.7

This table makes one thing immediately clear: non-Hispanic White men and women carry the highest non-Hodgkin lymphoma incidence rates of any group tracked by SEER, at 24.2 and 16.5 per 100,000, respectively — noticeably above the “all races” average in both sexes. Men consistently show higher rates than women within every single racial and ethnic category, a pattern that has held steady for decades and is thought to relate to a mix of biological, occupational, and possibly immune-related exposure differences between men and women that researchers are still working to fully explain.

At the other end of the spectrum, Non-Hispanic Asian/Pacific Islander populations report the lowest incidence rates among men (16.7), while Non-Hispanic Black women report the lowest rate among women (11.9). For SEO and reader value, this breakdown is important because it helps dispel the misconception that cancer risk is uniform across populations — genetics, environmental exposure, immune conditions like HIV, and even geographic clustering of certain NHL subtypes all play measurable roles in why some demographic groups see meaningfully different rates of this disease than others.

Non-Hodgkin Lymphoma Death Rate By Race And Ethnicity In US 2026

Data Source: Centers for Disease Control and Prevention, National Center for Health Statistics, U.S. Mortality Data, 2020–2024, age-adjusted.

Visual Snapshot — Female vs Male Death Rate (All Races):

Male     ██████████████████████████ 6.2
Female   ███████████████            3.6

The mortality figures mirror the incidence patterns almost exactly — Non-Hispanic White men and women again post the highest death rates (6.6 and 3.8 per 100,000), while men die from NHL at roughly double the rate of women across virtually every racial and ethnic group. This consistency between incidence and mortality data across categories strengthens confidence in the reliability of the underlying federal reporting, since two independently collected datasets (SEER for new cases, CDC/NCHS for deaths) are telling essentially the same demographic story.

Non-Hispanic White Americans aren’t necessarily surviving NHL at a lower rate than other groups; they’re simply being diagnosed with it more often to begin with, which naturally produces more deaths in absolute and rate terms within that population over time.

Non-Hodgkin Lymphoma Age Distribution Of New Cases In US 2026

Data Source: National Cancer Institute, SEER 21 Registries, 2019–2023, all races, both sexes.

Visual Snapshot — New Case Share by Age Group:

<20     █ 1.6%
20-34   ██ 3.6%
35-44   ███ 4.8%
45-54   ██████ 9.5%
55-64   █████████████ 20.0%
65-74   ██████████████████ 28.7%
75-84   ███████████████ 23.0%
>84     ██████ 8.8%

This age-distribution table confirms that non-Hodgkin lymphoma is overwhelmingly a disease of older adulthood, with people aged 65 to 74 accounting for the single largest share of new diagnoses at 28.7%, followed closely by the 75–84 age group at 23.0%. Combined, Americans aged 55 and older make up more than 80% of all new NHL diagnoses, which strongly reinforces why the median diagnosis age sits at 68 and why screening conversations around unexplained swollen lymph nodes, night sweats, or persistent fatigue become especially relevant once someone crosses into their late fifties and sixties.

That said, the under-20 and 20–34 age brackets still register a combined 5.2% of cases, a reminder that NHL is not exclusively a disease of the elderly — pediatric and young-adult NHL cases do occur and often behave differently, tend to be more aggressive, but generally respond very well to intensive chemotherapy protocols designed specifically for younger, healthier patients. For families and patients researching this topic, understanding where their own age group falls on this curve can help set realistic expectations about both risk and, generally, more favorable prognosis at younger ages.

Non-Hodgkin Lymphoma Age Distribution Of Deaths In US 2026

Data Source: Centers for Disease Control and Prevention, National Center for Health Statistics, U.S. Mortality Data, 2020–2024.

Visual Snapshot — Death Share by Age Group:

75-84   █████████████████████ 33.9%
65-74   ████████████████ 25.2%
>84     ██████████████ 22.6%
55-64   ███████ 11.7%
45-54   ██ 3.8%

Comparing this table to the previous one reveals a meaningful shift: while the 65–74 group has the highest share of new diagnoses, the 75–84 group has the highest share of deaths at 33.9%, and together with the over-84 group, patients aged 75 and older account for a combined 56.5% of all NHL deaths. This gap between the peak diagnosis age bracket and the peak death age bracket suggests that the disease’s real toll shows up several years after initial diagnosis, once the cumulative effects of aging, comorbidities, and disease progression converge in the oldest patients.

The median age at death of 76, compared to a median diagnosis age of 68, supports this same conclusion — most patients are living a number of years past diagnosis, and it is typically the oldest, frailest patients who are least able to tolerate aggressive treatment who ultimately succumb to the disease. This is a critical insight for families of older NHL patients, because it underscores why oncologists often tailor less intensive but still effective treatment plans for patients in their late seventies and eighties, balancing quality of life against the risks of standard high-dose chemotherapy regimens.

If you’re comparing this pattern against other blood cancers, our detailed breakdown of lymphoma cancer statistics in the US puts Hodgkin and non-Hodgkin lymphoma side by side using the same government data sources referenced throughout this report.

Non-Hodgkin Lymphoma 5-Year Survival Rate By Stage In US 2026

Data Source: National Cancer Institute, SEER 17 Registries, 2016–2022, Ann Arbor Staging System.

Visual Snapshot — Survival Rate by Stage:

Stage I    ████████████████████████ 87.6%
Stage II   ██████████████████████   79.7%
Stage III  ████████████████████     74.0%
Stage IV   █████████████████        63.6%
Unknown    ███████████████████      71.9%

Stage clearly matters enormously in non-Hodgkin lymphoma outcomes: patients caught at Stage I enjoy an 87.6% five-year survival rate, roughly 24 percentage points higher than the 63.6% survival seen in Stage IV patients, whose disease has already spread diffusely through the body. Unfortunately, the table also shows that 37% of all NHL cases are diagnosed at Stage IV — by far the largest single group — which reflects how difficult NHL can be to catch early, since its symptoms (swollen lymph nodes, fatigue, night sweats) are often mild, intermittent, or mistaken for less serious conditions in the early stages.

Encouragingly, even Stage IV NHL carries a substantially better prognosis than late-stage versions of many solid tumor cancers, largely because lymphomas as a category tend to respond unusually well to systemic chemotherapy and immunotherapy regardless of how far they’ve spread — this is fundamentally different from cancers where staging correlates almost linearly with treatability. For patients and caregivers, this table should offer some genuine reassurance: a late-stage NHL diagnosis is serious, but a 63.6% five-year survival rate is still meaningfully favorable compared to late-stage outcomes in many other major cancer types.

Non-Hodgkin Lymphoma Survival Rate By Subtype In US 2026

Data Source: National Cancer Institute, SEER Program period-analysis modeling; SEER Cancer Stat Facts, DLBCL.

Visual Snapshot — Survival by Subtype:

MZL      ████████████████████████ 92.5%
FL       ███████████████████████  91.6%
CLL/SLL  ██████████████████████   87.3%
DLBCL-I  ███████████████████      79.9%
Overall  ██████████████████       74.3%

Not all forms of non-Hodgkin lymphoma behave the same way, and this table illustrates why oncologists always specify subtype before discussing prognosis with a patient. Marginal zone lymphoma and follicular lymphoma, both classified as slow-growing (indolent) subtypes, post the strongest survival outcomes at 92.5% and 91.6% respectively — figures well above the 74.3% overall NHL average — largely because these cancers progress slowly enough that patients often live for many years, sometimes decades, even without aggressive upfront treatment.

DLBCL, the most common and typically aggressive subtype, shows a somewhat lower but still strong 79.9% survival rate when caught at Stage I, demonstrating that “aggressive” doesn’t necessarily mean “less treatable” — in fact, aggressive lymphomas often respond faster and more completely to intensive chemoimmunotherapy than slow-growing types, which paradoxically can be harder to cure outright even though they progress more gradually. This nuance is one of the most important things a newly diagnosed patient can learn: subtype, not just stage, fundamentally shapes both treatment strategy and long-term outlook.

Non-Hodgkin Lymphoma Treatment Options In US 2026

Data Source: National Cancer Institute, PDQ Non-Hodgkin Lymphoma Treatment Summary; National Cancer Institute, Advances in Lymphoma Research.

Visual Snapshot — Treatment Pathway Overview:

Diagnosis → Staging → Chemotherapy/Immunotherapy → Response Check
                                   ↓ (if relapsed/refractory)
                         CAR T-Cell Therapy / Targeted Therapy / Stem Cell Transplant

Treatment for non-Hodgkin lymphoma has genuinely transformed over the past two decades, moving from a near-total reliance on chemotherapy to a much more layered toolkit. Chemotherapy combined with immunotherapy drugs like rituximab remains the backbone of first-line treatment for most subtypes, but four CAR T-cell therapies are now FDA-approved specifically for relapsed or refractory large B-cell lymphoma and follicular lymphoma, representing one of the biggest treatment breakthroughs in blood cancer care during the last ten years — patients whose T-cells are genetically reprogrammed to hunt down lymphoma cells are seeing durable remissions in situations where standard chemotherapy had previously failed.

For patients whose disease doesn’t respond to initial therapy, oncologists now have a genuine sequence of options rather than a single fallback: targeted therapy drugs that block specific growth pathways, stem cell transplantation to rebuild the bone marrow after intensive treatment, and CAR T-cell therapy as a next-generation option for the toughest, most treatment-resistant cases. Ongoing research, including efforts to reduce chemotherapy intensity in lower-risk patients without sacrificing cure rates, continues to push this treatment landscape forward, meaning the options available to someone diagnosed with NHL in 2026 are meaningfully broader and generally gentler than they were even a decade ago.

Non-Hodgkin Lymphoma Incidence And Mortality Trends In US 2026

Data Source: National Cancer Institute, SEER Joinpoint Trend Analysis; SEER Cancer Stat Facts, Non-Hodgkin Lymphoma.

Visual Snapshot — Long-Term Survival Improvement:

1975   ████████████ 46.6%
2000   ████████████████ 64.7%
2016   ███████████████████ 78.2%
2022   ██████████████████ 74.3%

The long-view trend data is arguably the most encouraging part of this entire report: NHL death rates have been falling by roughly 2.4% every year, a decline pace that is actually faster than the 0.6% annual drop in new case rates, meaning survival gains are outpacing the modest reduction in how often the disease is diagnosed in the first place. Five-year relative survival has climbed from under 50% in the mid-1970s to 74.3% in the most recent reporting period — a genuinely dramatic, multi-decade improvement driven by the successive introduction of rituximab in the early 2000s, targeted small-molecule drugs in the 2010s, and CAR T-cell therapies in the last several years.

It’s worth noting that the most recent single-year survival figures dip slightly from the peak seen around 2016 (78.2%) to 74.3% in the newest cohort, which is a normal statistical artifact of how 5-year survival is calculated for the most recent years — later cohorts simply haven’t had the full five years of follow-up time needed to confirm final outcomes, so these numbers tend to firm back up as more follow-up data comes in over the next reporting cycles. For anyone tracking this disease over time, the consistent, decade-over-decade direction — fewer deaths, better survival, more treatment options — is the real headline, far more meaningful than any single year’s fluctuation.

Readers researching related blood cancers may also find it useful to review our companion resource on leukemia statistics in the US, which tracks similar SEER-based incidence and survival trends, alongside our broader cancer statistics in the US overview covering all major cancer types reported by federal registries.

Disclaimer: This research report is compiled from publicly available sources. While reasonable efforts have been made to ensure accuracy, no representation or warranty, express or implied, is given as to the completeness or reliability of the information. We accept no liability for any errors, omissions, losses, or damages of any kind arising from the use of this report.

Email ID:

Please enable JavaScript in your browser to complete this form.

Email

Email *

SUBSCRIBE